Corbus Pharmaceuticals Holdings Inc CRBP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/14/24 EDT
42.99UNCH (UNCH)
Volume
29,344
Close
42.99UNCH (UNCH)
Volume
76,652
52 week range
3.03 - 49.87
Loading...
  • Open42.44
  • Day High43.64
  • Day Low42.37
  • Prev Close42.99
  • 52 Week High49.87
  • 52 Week High Date03/13/24
  • 52 Week Low3.03
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap459.421M
  • Shares Out10.69M
  • 10 Day Average Volume0.26M
  • Dividend-
  • Dividend Yield-
  • Beta2.53
  • YTD % Change611.75

KEY STATS

  • Open42.44
  • Day High43.64
  • Day Low42.37
  • Prev Close42.99
  • 52 Week High49.87
  • 52 Week High Date03/13/24
  • 52 Week Low3.03
  • 52 Week Low Date11/13/23
  • Market Cap459.421M
  • Shares Out10.69M
  • 10 Day Average Volume0.26M
  • Dividend-
  • Dividend Yield-
  • Beta2.53
  • YTD % Change611.75

RATIOS/PROFITABILITY

  • EPS (TTM)-6.97
  • P/E (TTM)-6.17
  • Fwd P/E (NTM)-7.05
  • EBITDA (TTM)-36.792M
  • ROE (TTM)-59.52%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-36,090.23%
  • Debt To Equity (MRQ)13.36%

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Corbus Pharmaceuticals Holdings Inc

 

Profile

MORE
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913...
Alan Holmer J.D.
Independent Chairman of the Board
Yuval Cohen Ph.D.
Chief Executive Officer, Director
Sean Moran CPA
Chief Financial Officer
Address
500 River Ridge Drive
Norwood, MA
02062
United States

Top Peers

SYMBOLLASTCHG%CHG
SLRN
ACELYRIN Inc
4.73UNCHUNCH
LRMR
Larimar Therapeutics Inc
7.88UNCHUNCH
PEPG
PepGen Inc
13.99UNCHUNCH
ALLO
Allogene Therapeutics Inc
2.96UNCHUNCH
KRRO
Korro Bio Inc
50.05UNCHUNCH